LEADER 05491nam 2200433 450 001 9910830340303321 005 20230715102714.0 010 $a1-119-76499-8 010 $a1-119-76497-1 035 $a(MiAaPQ)EBC7261979 035 $a(Au-PeEL)EBL7261979 035 $a(OCoLC)1382695500 035 $a(EXLCZ)9926959370600041 100 $a20230715d2023 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDrug compounding for veterinary professionals /$fLauren R. Eichstadt Forsythe, Alexandria E. Gochenauer 210 1$aHoboken, NJ :$cJohn Wiley & Sons, Inc.,$d[2023] 210 4$d©2023 215 $a1 online resource (174 pages) 311 08$aPrint version: Eichstadt Forsythe, Lauren R. Drug Compounding for Veterinary Professionals Newark : John Wiley & Sons, Incorporated,c2023 9781119764960 320 $aIncludes bibliographical references and index. 327 $aCover -- Title Page -- Copyright Page -- Contents -- Foreword -- Preface -- List of Acronyms -- About the Companion Website -- Introduction -- Chapter 1 Compounding Regulations -- Organizations and Regulatory Agencies Involved with Compounding -- Food and Drug Administration -- United States Pharmacopeia -- Drug Enforcement Administration -- State Boards of Pharmacy -- State Veterinary Boards -- Compliance Policy Guides and Guidance for Industry Documents -- What Is Compounding? -- The Food, Drug, and Cosmetic Act -- Animal Medicinal Drug Use Clarification Act -- Preparing Compounds from an Approved Product or a Pure Drug Powder -- Federal Versus State Law [8] -- Office Use Compounding -- Drug Quality and Security Act [26] -- Finding Additional Information -- References -- Chapter 2 Risk-Benefit Analysis of Compounded Medications -- Benefits of Compounded Products -- Dosage Form -- Flavoring -- Dosage Strength -- Eliminating Ingredients -- Availability Issues -- Appropriate Use of Compounded Medications -- FDA-Approved Drugs -- Compounded Medication Risks -- Compounded (USP) Versus Manufactured (cGMP) -- Risks Associated with Compounded Medications - A Look at the Literature -- Studies Showing Incorrect Potency -- Studies Showing Lack of Stability -- Studies Showing Lack of Efficacy -- Risks Associated with Specific Types of Compounds -- Active Ingredient Source Decisions -- Patient-Specific Compounding Versus Office Use Compounding -- Adverse Event Reporting -- Identifying Potential Formulation Issues -- Drugs Recalls -- Selecting a Compounding Pharmacy -- Client Education -- Reducing Risk in Practice -- Conclusion -- References -- Chapter 3 Beyond-Use Dating -- Factors Considered When Assigning BUDs and Expiration Dates -- USP Default BUDs -- Stability Studies -- Evaluating Stability Studies -- Determining BUDs for In-House Formulations. 327 $aBUD Considerations When Prescribing Compounded Medications -- Conclusion -- References -- Chapter 4 Identifying High-Quality Compounding Pharmacies -- Case Study 1 -- Case Study 2 -- What to Evaluate -- General Practices -- Staff Skill Level -- Familiarity with Veterinary Medicine -- Pharmacy Culture -- Ways to Evaluate Compounding Pharmacies -- Looking Beyond the Pharmacy's Website -- What to Look for on a Tour -- Questions to Ask the Pharmacist in Charge -- Conclusion -- References -- Chapter 5 Formulation Development -- Dosage Forms -- Oral Administration -- Transdermal Administration -- Topical Administration -- Otic Administration -- Other Routes of Administration -- Ingredients -- Organic Salts -- Inorganic Salts -- Oral Liquid Medications -- Oral Solid Medications -- Emulsions -- Transdermal Medications -- Cream, Gel, and Ointment Medications -- Hazardous Drugs -- Beyond-Use Dates -- Formulation Resources -- Calculations -- Measurements Used in Compounding -- Displacement Factor -- Capsules: Packing Statistics -- Packing Statistic of Drug -- Average Weight of Ingredients -- Percentage of Drug per Capsule Using Bulk Powder -- Percentage of Drug per Capsule Using Manufactured Tablet -- Percentage/Amount of Filler per Capsule -- Conversion to Grams -- Compounding Formulations to Avoid -- Formulation Development Process -- Developing a Compounding Formula: Example 1 (USP Compounding Compendium) -- Developing a Compounding Formula: Example 2 (Stability-Indicating Assay) -- Compounding Formulation Assessment -- References -- Chapter 6 Compounding in House -- Documentation -- Master Formulation Record -- Compounding Record -- Formulation Record Components -- Quality Assurance and Quality Control -- Labeling -- Packaging and Storage -- Compounding Techniques -- Trituration -- Sifting -- Geometric Dilution -- Wetting -- Colored Tracers -- Equipment. 327 $aMortars and Pestles -- Glassware -- Containers -- Scales -- Spatulas and Measuring Devices -- Equipment Cleaning -- Training -- Formulation Instructions -- Species-Specific Information -- Flavoring -- Toxicities -- Potency Designations -- Feasibility for a Veterinary Clinic -- References -- Index -- EULA. 606 $aVeterinary drugs 615 0$aVeterinary drugs. 676 $a636.08951 700 $aEichstadt Forsythe$b Lauren R.$01701024 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830340303321 996 $aDrug compounding for veterinary professionals$94084476 997 $aUNINA